Monday, 16 Sep 2019

You are here

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

According to Lilly, there are 1.6 million people in the US with ankylosing spondylitis, but only 15% of patients with the condition are taking biologic therapies.

Approval is based on the COAST trials in AS. The COAST-V trial studied IXE in biologic naive AS/SpA patients and the COAST-W trial involved patients previously to TNF inhibitors.

In COAST-V, IXE achieved ASAS40 of 48%, compared with 18% of placebo (P < .0001) treated patients. ASAS40 response rates in COAST-W were 25% with ixekizumab vs 13% with placebo (P <0.05).

There are no serious "boxed" warnings.  Other warnings and precautions include:

  • Serious infections
  • Tuberculosis (TB): Evaluate for TB prior to initiating treatment
  • Hypersensitivity: If a serious allergic reaction occurs, discontinue TALTZ
  • Inflammatory Bowel Disease: Crohn’s disease and ulcerative colitis, including exacerbations, occurred in clinical trials

Ixekizumab (IXE) was previously \approved in March 2016 for plaque psoriasis and in December 2017 for psoriatic arthritis.

This will be the second IL-17 targeted biologic (along with Cosentyx) approved by the FDA for ankylosing spondylitis.



The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).

ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.

Biologic Therapy Improves Psoriasis and Reduces CV Inflammation

Psoriasis confers a significant risk of comorbidity, but is psoriasis associated with increased coronary inflammation and is this risk attenuated by biologic therapy? JAMA Cardiology has published a cohort study of 134 consecutive patients with moderate to severe psoriasis, showing that biologic therapy was associated with a significant decrease in coronary inflammation as assessed by perivascular fat attenuation index, a marker of coronary inflammation associated with cardiovascular outcomes. Patients not receiving biologic therapy had no change in perivascular fat attenuation index at 1 year.

Joint Surgery Rates Remain High in Psoriatic Arthritis

The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.